

ACHILLION PHARMACEUTICALS INC  
Form SC 13G  
March 26, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

Achillion Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

00448Q201

(CUSIP Number)

October 31, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which the Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

CUSIP No. 00448Q201

13G

1. NAMES OF REPORTING PERSONS

Blackwell Partners, LLC

I.R.S. IDENTIFICATION NOS. OF  
ABOVE PERSONS (ENTITIES  
ONLY)

20-8075455

2. CHECK THE APPROPRIATE BOX  
IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF  
ORGANIZATION

Georgia

5. SOLE VOTING POWER

NUMBER OF

SHARES 5,240,892

BENEFICIALLY OWNED BY

EACH

REPORTING PERSON 0

WITH 7. SOLE DISPOSITIVE POWER

5,240,892

8. SHARED DISPOSITIVE POWER

0

9. AGGREGATE AMOUNT  
BENEFICIALLY OWNED BY  
EACH REPORTING PERSON

5,240,892

10.

CHECK IF THE AGGREGATE  
AMOUNT IN ROW 9 EXCLUDES  
CERTAIN SHARES ..

11.

PERCENT OF CLASS  
REPRESENTED BY AMOUNT IN  
ROW 9

12.

5.4%  
TYPE OF REPORTING PERSON

IV

CUSIP No. 00448Q201

13G

1. NAMES OF REPORTING PERSONS

Duke University

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

56-0532129

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) £  
(b) x

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

North Carolina

5. SOLE VOTING POWER

NUMBER OF SHARES

0

BENEFICIALLY OWNED BY EACH

6. SHARED VOTING POWER

5,240,892

REPORTING PERSON WITH

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

5,240,892

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,240,892

10. CHECK IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES

CERTAIN SHARES

..

**11.** PERCENT OF CLASS  
REPRESENTED BY AMOUNT IN  
ROW 9

**12.** 5.4%  
TYPE OF REPORTING PERSON

OO

CUSIP No. 00448Q201

13G

1. NAMES OF REPORTING PERSONS

DUMAC, Inc.

I.R.S. IDENTIFICATION NO. OF  
ABOVE PERSONS (ENTITIES  
ONLY)

90-0754895

2. CHECK THE APPROPRIATE BOX  
IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF  
ORGANIZATION

North Carolina

5. SOLE VOTING POWER

NUMBER OF  
SHARES

0

BENEFICIALLY OWNED BY  
EACH REPORTING PERSON

6. SHARED VOTING POWER

EACH

5,240,892

REPORTING  
PERSON

7. SOLE DISPOSITIVE POWER

WITH

0

8. SHARED DISPOSITIVE POWER

5,240,892

9. AGGREGATE AMOUNT  
BENEFICIALLY OWNED BY  
EACH REPORTING PERSON

5,240,892

10. CHECK IF THE AGGREGATE  
AMOUNT IN ROW 9 EXCLUDES

CERTAIN SHARES

..

**11.** PERCENT OF CLASS  
REPRESENTED BY AMOUNT IN  
ROW 9

**12.** 5.4%  
TYPE OF REPORTING PERSON

IA



Blackwell Partners, LLC (“Blackwell”), Duke University, and DUMAC, Inc. (“DUMAC”), (collectively, the “Reporting Persons”) are filing this Statement of Beneficial Ownership on Schedule 13G to report the shares of Common Stock, par value \$0.001 per share (the “Common Stock”) of Achillion Pharmaceuticals, Inc., a Delaware corporation (“Achillion”) over which they could acquire beneficial ownership if they were to terminate their investment management agreement with RA Capital Management, LLC.

DUMAC is a North Carolina non-profit corporation. DUMAC manages the investment of endowment and other assets of Duke University and Blackwell. DUMAC does not hold legal title to its clients’ assets. The members of the board of directors of DUMAC are appointed by the executive committee of the board of trustees of Duke University.

Blackwell is a Georgia limited liability company that is managed by an entity that qualifies as a support corporation of Duke University under Section 509(a)(3) of the Internal Revenue Code.

**Item 1(a). Name of Issuer:**

Achillion Pharmaceuticals, Inc.

**Item 1(b). Address of Issuer’s Principal Executive Offices:**

300 George Street

New Haven, CT 06511

**Item 2(b). Name of Person Filing:**

Blackwell Partners, LLC

Duke University

DUMAC, Inc.

**Item 2(b). Address of Principal Business Office:**

Blackwell Partners, LLC

c/o DUMAC, Inc.

280 S Mangum St., Suite 210

Durham, NC 27701

Duke University

c/o DUMAC, Inc.

280 S Mangum St., Suite 210

Durham, NC 27701

DUMAC, Inc.

280 S Mangum St., Suite 210

Durham, NC 27701

**Item 2(c). Citizenship:**

Blackwell Partners, LLC

Georgia

Duke University

North Carolina

DUMAC, Inc.

North Carolina

**Item 2(d). Title of Class of Securities**

Common Stock, \$.001 par value per share

**Item 2(e). CUSIP Number:**

00448Q201

**Item 3.** If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Act.
- (b) Bank as defined in Section 3(a)(6) of the Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Act.
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940.
- (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).
- (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F).
- (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G).
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
- (j) Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

**Item 4. Ownership**

As of the date of this filing, Blackwell beneficially owns 5,240,892 shares of Common Stock of Achillion, which constitutes approximately 5.4% of Achillion's outstanding Common Stock as reported in its Annual Report on Form

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

10-K for the year ended December 31, 2013 filed on March 7, 2014. Of the above 5,240,892 shares of Achillion's Common Stock, Blackwell has sole voting and dispositive power over 5,240,892 shares of Common Stock of Achillion and shared dispositive power over 0 shares of Common Stock of Achillion.

Duke University beneficially owns, and has shared voting and dispositive power over, 5,240,892 shares of Common Stock of Achillion, which constitutes approximately 5.4% of Achillion's outstanding Common Stock. DUMAC beneficially owns, and has shared voting and dispositive power over, 5,240,892 shares of Common Stock of Achillion, which constitutes approximately 5.4% of Achillion's outstanding Common Stock.

This Schedule 13G has been filed for informational purposes to reflect that DUMAC makes investment decisions for each of Duke University and Blackwell. Beneficial ownership of Achillion's shares beneficially owned by Blackwell, Duke University, and DUMAC is also reflected in Schedule 13D, as amended, filed by RA Capital Management, LLC. The Reporting Persons disclaim beneficial ownership over the shares of Common Stock reported above.

**Item 5. Ownership of Five Percent or Less of Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

**Item 6. Ownership of More Than 5 Percent on Behalf of Another Person**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable.

**Item 9. Notice of Dissolution of Group**

Not Applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**Exhibits Exhibit 99-1**

Joint Filing Agreement, dated March 26, 2014, by and among Blackwell, DUMAC, and Duke University.

[Signature Page Follows]

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATED: March 26, 2014

Blackwell Partners, LLC

By: /s/ Robert E. McGrail  
Name: Robert E. McGrail  
Title: Secretary  
DUMAC, Inc.

Duke University

By: /s/ Robert E. McGrail  
Name: Robert E. McGrail  
Title: Secretary  
DUMAC, Inc.

DUMAC, Inc.

By: /s/ Robert E. McGrail  
Name: Robert E. McGrail  
Title: Secretary  
DUMAC, Inc.